CHRS

0.36984.47%
CW

Charles W. Newton

Independent Director

Mr. Charles W. Newton, also known as Charlie, is an Independent Director of Keros Therapeutics, Inc. from March 9, 2026. He serves as Director of DELFI Diagnostics, Inc. from April 2026. He is an Independent Director of Novavax, Inc. from 2025. He serves as Chief Financial Officer at Lyell Immunopharma, Inc. since February 2021 until October 31, 2025. Mr. Newton was Independent Director at 2seventy bio, Inc. since March 20, 2024 until May 13, 2025. He served as a Director at Carmot Therapeutics, Inc. from July 2023 to January 2024. He serves as Independent Director at Coherus Oncology, Inc. (formerly known as Coherus BioSciences, Inc.) since May 2022. Prior to Lyell, he was at Bank of America Merrill Lynch, where he served as Managing Director and Co-Head of Healthcare Investment Banking in the Americas from 2015 to 2021. Previously, Mr. Newton co-Headed BofA Securities' healthcare investment banking practice in the Americas and served as its Managing Director. He advised biotechnology companies on mergers, acquisitions and financings including initial public offerings, follow-on common stock offerings, convertible debt offerings, investment grade note offerings and private placements. Prior to joining BofA Securities, Mr. Newton served as Managing Director and co-Headed Credit Suisse's healthcare investment banking practice in the Americas from 2010 to 2015 and he served as Managing Director and Headed Morgan Stanley's western region healthcare investment banking practice. He served as Managing Director of Morgan Stanley since December 2005 until September 2010. Earlier in his career, he was an Investment Banking Analyst with Lehman Brothers and a Financial Analyst with Mercer Global Advisors. He holds MBA from the Tuck School at Dartmouth College in 1997. He holds BS in Finance from Miami University in 1992.

Positions